Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 940 participants.
Also called NCT06187311
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 940 participants
- Registry
-
NCT06187311
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT06187311. Randomized; no masking; primary purpose treatment. Start 2023-01-12 (actual); primary completion 2026-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation
- Acronym
- REVISE-AF
- Condition
- Atrial Fibrillation
- Condition
- Anticoagulant Adverse Reaction
- Intervention (Drug)
- Rivaroxaban 20 MG
- Intervention (Drug)
- Rivaroxaban 15 MG
- Lead sponsor
- Korea University Anam Hospital
Record details
- Record id
cardio:ct-nct06187311- Content hash
3607e6ac854b2ec2ab9a906150471ec7e31b1819a09ea697cf96f0f80683aff3